The findings showed that compared with the use of free TGF-β1 siRNA, EVs carrying TGF-β1 siRNA effectively reduced the level of TGF-β1 in the targeted tumor cells, significantly lowering the viability and migration ability of mouse sarcoma cells[77]. The gene discussed is TGFB1; the disease is neoplasm.